Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab in Advanced HCC and Chronic HCV
NCT01008358Phase 2Completed
- Sponsor
- Universidad de Navarra
- Start
- Dec 2008
- Primary completion
- May 2012
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tremelimumab in hepatocellular carcinoma (HCC), chronic hepatitis C virus infection (CHC), sponsored by Universidad de Navarra. Started Dec 2008; status: completed.
02
Drugs
tremelimumab
03
Conditions
hepatocellular carcinoma (HCC)chronic hepatitis C virus infection (CHC)
Beyond the preview
Go deeper on NCT01008358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01008358.